Although respiratory syncytial virus (RSV) has been a high priority for vaccine development for over 50 years now, still no vaccine is available and none has yet demonstrated sufficient promise to move to licensure. The success of RSV immune prophylaxis and the availability of ever more powerful tools to study the immune response and pathogenesis of disease, combined with the ability to construct a wide variety of vaccines using different vaccine platforms, give us grounds to believe that an RSV vaccine is within reach. This book brings together in one source what is currently known about the virus: its clinical and epidemiologic features; the host response and pathogenesis of the disease; vaccines, vaccine platforms, and treatment; and animal and tissue culture models of RSV infection. It is designed to organize the critical information relevant to RSV vaccine development, facilitate the assimilation of data, and speed progress toward producing a safe and effective vaccine.
From the reviews:
"I enjoyed the book: as an immunologist who has spent 10 years working on RSV there were a number of novel insights and it was nice to see it all in one place. ... I will be recommending it to PhD students and Postdocs starting out on RSV research ... . also recommend it to people who have been working with RSV for a while to dip in and out of to fill any gaps in the general knowledge." (John Tregoning, Immunology News, May, 2014)
"I enjoyed the book: as an immunologist who has spent 10 years working on RSV there were a number of novel insights and it was nice to see it all in one place. ... I will be recommending it to PhD students and Postdocs starting out on RSV research ... . also recommend it to people who have been working with RSV for a while to dip in and out of to fill any gaps in the general knowledge." (John Tregoning, Immunology News, May, 2014)